Last reviewed · How we verify

Azienda Sanitaria-Universitaria Integrata di Udine — Portfolio Competitive Intelligence Brief

Azienda Sanitaria-Universitaria Integrata di Udine pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Fluconazol Fluconazol marketed Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Azienda Sanitaria-Universitaria Integrata di Udine:

Cite this brief

Drug Landscape (2026). Azienda Sanitaria-Universitaria Integrata di Udine — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/azienda-sanitaria-universitaria-integrata-di-udine. Accessed 2026-05-18.

Related